The patented, medical devices Advitos's treatments can support three organs simultaneously—liver, lungs, and kidneys. The procedure also regulates the pH balance of the blood. This can also benefit COVID-19 patients, as PD Dr. med. Bernhard Kreymann, nephrologist and inventor of the technology, explains:
"Most people who die from COVID-19 are of a certain age and ultimately suffer from multiple organ failure (MOF). Simply put, these patients' kidneys, heart, liver, and lungs are malfunctioning, adding severe pathology to the respiratory failure caused by the coronavirus. To help these patients, it makes sense to use a device capable of treating all of these organs simultaneously to achieve better outcomes."
The devices have already been used in twenty hospitals in Germany over the past two years. Treating patients' organs with a single procedure is intended to simplify the tasks and complexity of treatments for doctors and nursing staff.
“Enormous talent and groundbreaking ideas”
For the promotion of EIC Almost 4,000 startups and small businesses applied. Of these, over 1,400 focused on testing, treatment, and prevention of the coronavirus. After virtual interviews with selected applicants, 36 companies were selected to receive funding to further combat the coronavirus. Advitos is one of only four selected companies from Germany. The EIC has a total of €314 million in funding, of which €174 million will be provided in the form of equity investments. Since its launch in mid-2019, the EIC's Accelerator Pilot Project has offered the option of direct equity investments of up to €15 million, in addition to support through grants of up to €2.5 million.
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said:
"The tremendous talent and groundbreaking ideas of innovative European companies give us hope. By increasing our support for the European Innovation Council, we are unlocking their potential and can thus better address the coronavirus and support Europe's recovery. The EIC has responded swiftly to the coronavirus crisis and demonstrated the flexibility and effectiveness of EU funding."
Bernard Kreymann is pleased about the support:
"We are honored and proud to receive the support of the European Innovation Council. The funding we receive will further develop the ADVOS therapy, thus providing the opportunity to further improve the survival chances of Covid-19 patients."
